These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20653799

  • 41. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
    Garmendia F, Brown AS, Reiber I, Adams PC.
    Curr Med Res Opin; 2000 Jul; 16(3):208-19. PubMed ID: 11191012
    [Abstract] [Full Text] [Related]

  • 45. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS, Kim SH, Kim JK, Ko SH, Ko JE, Park SJ, Park MG, Lee JH, Hyon MS.
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, Gogineni S, Wang P.
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [Abstract] [Full Text] [Related]

  • 49. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS.
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
    Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.
    Am J Cardiovasc Drugs; 2010 May; 10(3):175-86. PubMed ID: 20524719
    [Abstract] [Full Text] [Related]

  • 53. Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Folse HJ, Goswami D, Rengarajan B, Budoff M, Kahn R.
    Atherosclerosis; 2014 Sep; 236(1):154-61. PubMed ID: 25050538
    [Abstract] [Full Text] [Related]

  • 54. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
    Reckless J, Davies G, Tunceli K, Hu XH, Brudi P.
    Value Health; 2010 Sep; 13(6):726-34. PubMed ID: 20561328
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
    Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M.
    Int J Clin Pract; 2008 Mar; 62(3):480-4. PubMed ID: 18201178
    [Abstract] [Full Text] [Related]

  • 57. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea.
    Jeong YJ, Kim H, Baik SJ, Kim TM, Yang SJ, Lee SH, Cho JH, Lee H, Yim HW, Choi IY, Yoon KH, Kim HS.
    J Clin Pharm Ther; 2017 Jun; 42(3):292-300. PubMed ID: 28251662
    [Abstract] [Full Text] [Related]

  • 58. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.
    Ann Intern Med; 2000 May 16; 132(10):769-79. PubMed ID: 10819699
    [Abstract] [Full Text] [Related]

  • 59. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
    Smart AJ, Walters L.
    S Afr Med J; 1994 Dec 16; 84(12):834-7. PubMed ID: 7570232
    [Abstract] [Full Text] [Related]

  • 60. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC, Wang HH, Liu KS.
    Int J Clin Pract; 2011 Dec 16; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.